Cullinan Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CGEM | CRVS | 2126.HK | LEGN | AVBP | AUTL | |
|---|---|---|---|---|---|---|
| Market cap | 767.61M | 889.16M | 1.11B | 4.43B | 665.16M | 367.30M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -5.1 | -9.9 | -3.0 | 21.7 | -3.6 | -2.2 |
| Price/book | 2.5 | 3.9 | 2.0 | 3.6 | 1.8 | 4.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +69.93% | +35.17% | −31.72% | −32.90% | −28.97% | +2.17% |
| Today | −20.70% | +7.53% | +7.91% | +6.01% | +3.61% | −2.47% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CGEM news ›Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies Initial data from the first multi-dose cohort of RA study to be presented Initial data from…
Transcript : Cullinan Therapeutics, Inc. - Special Call
Presenter SpeechNadim Ahmed All right. Well, good morning, everyone, and welcome to Cullinan Therapeutics Immunology Day. Today is an important milestone for Cullinan and also the way autoimmune... Transcript : Cullinan Therapeutics, Inc.…
Cullinan Therapeutics, Inc.: Relative Strength Chart - Stock Nasdaq
Compare Cullinan Therapeutics, Inc. with the company of your choice via a Relative Strength chart. Real-time CGEM price, Nasdaq stock exchange Relative Strength Chart Cullinan Therapeutics, Inc. Biotechnology & Medical Research All…
Cullinan Therapeutics Presents Initial Clinical Data for Cln-978, A Cd19xcd3 T Cell Engager, At the Eular 2026 Congress
Cullinan Therapeutics, Inc. announced that it will present initial clinical data from two ongoing Phase 1 studies of CLN-978, a CD19xCD3 T cell engager, at the European Alliance of Associations for...
Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Raised to Hold at Wall Street Zen
Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports. Check Out…
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
CLN-049 has received FDA Orphan Drug and Fast Track designations for relapsed/refractory acute myeloid leukemia. Cullinan Therapeutics (CGEM) has dosed the first patient in its potentially registrational Phase 2 study of CLN-049 for…
Cullinan Therapeutics Presents Initial Clinical Data for Cln-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus At Eular Congress
Cullinan Therapeutics, Inc. announced that initial clinical data from two ongoing Phase 1 studies evaluating CLN-978, a subcutaneously administered CD19xCD3 T cell engager, will be presented at the... announced that initial clinical data…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com4
- marketbeat.com1
- markets.financialcontent.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.